Global Neoantigen Cancer Vaccine Market Report and Forecast 2025-2034

Global Neoantigen Cancer Vaccine Market Outlook

The global neoantigen cancer vaccine market size was valued at USD 116.74 million in 2024, driven by the rising investments in the research and development of the immunotherapy and rapid technological advancements in the healthcare sector. The market size is anticipated to grow at a CAGR of 69.43% during the forecast period of 2025-2034 to achieve a value of USD 13,431.43 million by 2034.

Neoantigen Cancer Vaccine: Introduction

Neoantigens are tumour-specific antigens produced in cancer cells that signify the changes which happen throughout the transformative process. These substances are truly unique to cancer tissue and have the potential to be identified by the immune system, resulting in the host's distinct anti-tumour activity. Neoantigens are peptides that are abnormally expressed as a result of genome alterations and are translated to form live peptides. They function as mechanisms for the immune system to distinguish between own and tumour tissue and have been identified as a novel target for cancer immunotherapies.

Global Neoantigen Cancer Vaccine Market Analysis

There are several key trends propelling the growth of the market size. The introduction of immunotherapy has emerged as a groundbreaking approach in cancer treatment and neoantigen cancer vaccines as a form of immunotherapy that specifically target neoantigens, which are tumour-specific antigens derived from genetic mutations has proven to be transformative in the approach to treat cancer. The increasing understanding of the immune system and its role in fighting cancer has fuelled the neoantigen cancer vaccines market demand further. The interest in neoantigen cancer vaccines has also spurred a significant increase in research and clinical trials which further has caused global neoantigen cancer vaccine market to witness dynamic growth.

Global Neoantigen Cancer Vaccine Market Segmentations

Based on segments, the market is divided into product type, neoantigen type, route of administration, cell, technology, delivery mechanism, applications, and region.

Market Breakup by Product Type

• Personalized Neoantigen Vaccine 

• Off-the Shelf Neoantigen Vaccine

Market Breakup by Neoantigen Type

• Synthetic Long Peptide (SLP)

• Dendritic Cell

• Nucleic Acid

• Tumour Cell

Market Breakup by Route of Administration

• Intravenous

• Intramuscular

• Transdermal

• Others

Market Breakup by Cell

• Autologous

• Allogenic

Market Breakup by Technology

• RNA Sequencing

• Whole Genome Sequencing

• HLA Typing

• Others

Market Breakup by Delivery Mechanism

• Liposomes

• Virosomes

• Electroporation

• Gene Gun

• Others

Market Breakup by Applications

• Lung, Melanoma

• Gastrointestinal

• Brain Cancer

• Others

Market Breakup by Region

• North America 

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Global Neoantigen Cancer Vaccine Market Scenario

The market has a lot of room to expand since immunotherapeutic treatment research and development is still ongoing, both in terms of understanding their mechanism of action, clinical relevance, and usability. The research and clinical trials in the field of immunotherapy is receiving enormous amounts of financial support from pharmaceutical corporations, biotech businesses, and academic institutions which has led to further growth capabilities for global neoantigen cancer vaccine market.

Global Neoantigen Cancer Vaccine Market: Competitor Landscape

The comprehensive EMR report provides an in-depth assessment of the market based on Porter's five forces model, along with giving a SWOT analysis. The report gives a detailed analysis of the following neoantigen cancer vaccine companies, covering their competitive landscape and the latest developments like mergers, acquisitions, investments, and expansion plans.

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• OSE Immunotherapeutics SA

• Gritstone bio, Inc.

• BioNTech SE

• F. Hoffmann-La Roche Ltd.

• Pfizer Inc.

• Merck & Co. Inc.

• Moderna Inc.

• Avidea Technologies, Inc.

• Eli Lilly and Company

• Vaccibody AS

• Agenus Inc.

• Novogene Co., Ltd.

• ZIOPHARM Oncology Inc.

• ISA Pharmaceuticals B.V.

• BrightPath Biotherapeutics Co., Ltd.

Key Highlights of the Report

Neoantigen Cancer Vaccine Market Report Snapshots

Neoantigen Cancer Vaccine Market Size

Neoantigen Cancer Vaccine Companies